logo

For the Inventor, By the Inventor

Tokyo, Japan

Nihon Medi-Physics Company, Limited


USPTO Granted Patents = 142

% Expired Patents = 25.4



Forward Citations = 1,122

Loading Chart...
Loading Chart...

198 inventors (with patents filed for the assignee):

goldMedal Nobuo Ueda (18 out of 19 patents)

silverMedal Makoto Azuma (17 out of 17 patents)

bronzeMedal Akio Hayashi (16 out of 50 patents)

4.  Masahito Toyama (14 out of 14 patents)

5.  Daisaku Nakamura (13 out of 13 patents)

6.  Masaaki Hazue (13 out of 14 patents)

7.  Akira Yokoyama (13 out of 14 patents)

8.  Yuki Okumura (12 out of 13 patents)

9.  Hirohiko Yamauchi (10 out of 10 patents)

10.  Shigemi Seri (10 out of 10 patents)

11.  Fumie Kurosaki (9 out of 9 patents)

12.  Ikuya Seki (9 out of 9 patents)

13.  Susumu Kondo (9 out of 9 patents)

14.  Osamu Ito (8 out of 8 patents)

15.  Toshiyuki Shinmura (8 out of 8 patents)


Core Competencies:
Radiopharmaceuticals
Ac-225 Production
Diagnostic Imaging Agents
Amyloid Affinity Compounds
Radioactive Halogen
Nuclear Medicine
Radiolabeled Antibodies
Fluorine Labeling
Image Processing Techniques
Cancer Diagnosis
Tumor Detection
Radiation Detection

142 patents:

1. 12618122 - Recovery method of Ra-226, production method of Ra-226 solution, and Ac-225 solution production method of Ac-225 solution (2026-05-05),
2. 12569578 - RI-LABELED HUMANIZED ANTIBODY (2026-03-10),
3. 12179149 - Method for purifyingRa-containing solution, method for producingRa target, and method for producingAc (2024-12-31),
4. 12046385 - Production method of 226Ra target, production method of 225Ac, and electrodeposition solution for producing 226Ra target (2024-07-23),
5. 11752223 - Method for producing Ac-225 solution and method for producing medicine using Ac-225 solution (2023-09-12),
6. 11701440 - Modified antibody and radioactive metal-labelled antibody (2023-07-18),
7. 11551826 - Method for producingAc (2023-01-10),
8. 11369701 - Ri-labeled humanized antibody (2022-06-28),
9. 11318216 - Method for producing radiohalogen-labeled compound and method for producing radiopharmaceutical (2022-05-03),
10. 11266753 - 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimtdazole derivative compound, and medicament including same (2022-03-08),
11. 11083804 - Precursor compound of radioactive halogen-labeled organic compound (2021-08-10),
12. 10953112 - Precursor compound of radioactive halogen-labeled organic compound (2021-03-23),
13. 10857245 - Diagnostic imaging agent for early bone metastasis from cancer (2020-12-08),
14. 10703726 - Method for producing radiopharmaceutical composition (2020-07-07),
15. 10472338 - Method for producing [F]flutemetamol (2019-11-12),
Company Overview
Nihon Medi-Physics Company, Limited, based in Tokyo, specializes in the development and production of radiopharmaceuticals, focusing on innovative solutions for nuclear medicine. The company is recognized for its expertise in the production of Ac-225, diagnostic imaging agents, and amyloid affinity compounds, contributing significantly to advancements in medical diagnostics and therapies. Their core technologies also encompass radiolabeled antibodies and fluorine labeling, positioning them as a key player in the field of radiopharmaceuticals.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

142 Patents

#437 in Tokyo

#890 in Japan

#5,724 in the World

Tokyo, JP
Tokyo, Japan

Nihon Medi-Physics Company, Limited

Forward Citations = 1,122

198 inventors:

goldMedal Nobuo Ueda (18 out of 19 patents)

silverMedal Makoto Azuma (17 out of 17 patents)

bronzeMedal Akio Hayashi (16 out of 50 patents)

4.  Masahito Toyama (14 out of 14 patents)

5.  Daisaku Nakamura (13 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nihon Medi-Physics Company, Limited. Retrieved from https://idiyas.com/company/nihon-medi-physics-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…